Yili Chuanning BiotechnologyLtd Dividends and Buybacks
Dividend criteria checks 3/6
Yili Chuanning BiotechnologyLtd is a dividend paying company with a current yield of 1.74% that is well covered by earnings.
Key information
1.7%
Dividend yield
-0.07%
Buyback Yield
| Total Shareholder Yield | 1.7% |
| Future Dividend Yield | 3.3% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | CN¥0.225 |
| Payout ratio | 37% |
Recent dividend and buyback updates
Recent updates
These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely
Oct 11
If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity
Jul 23We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease
May 31Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt
Feb 26Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, 301301 has been paying a dividend for less than 10 years.
Growing Dividend: 301301's dividend payments have increased, but the company has only paid a dividend for 2 years.
Dividend Yield vs Market
| Yili Chuanning BiotechnologyLtd Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (301301) | 1.7% |
| Market Bottom 25% (CN) | 0.5% |
| Market Top 25% (CN) | 2.1% |
| Industry Average (Biotechs) | 1.2% |
| Analyst forecast (301301) (up to 3 years) | 3.3% |
Notable Dividend: 301301's dividend (1.74%) is higher than the bottom 25% of dividend payers in the CN market (0.55%).
High Dividend: 301301's dividend (1.74%) is low compared to the top 25% of dividend payers in the CN market (2.15%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (37%), 301301's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (59.3%), 301301's dividend payments are covered by cash flows.